Introduction {#sec1-1}
============

Ayurveda descried five types of *Shwasa Roga* (pathological conditions concerned with difficulty in breathing and associated clinical conditions) and among these, *Tamaka Shwasa* is one.\[[@ref1][@ref2]\] *Tamaka Shwasa* is a "*Swantarta*" *Vyadhi*, that is, independent disease entity and having its own etiology, pathophysiology, and management. It is mentioned as *Yapya Vyadhi*, that is, a disease of the chronic nature and difficult to cure.\[[@ref3]\] *Tamaka Shwasa* is basically a disorder of *Pranavaha Srotas* while other *Srotas* are also vitiated.\[[@ref4]\] The parallel disease entity in contemporary medical science to this disorder is Bronchial Asthma. Bronchial Asthma is a chronic inflammatory condition of the lung airways resulting in episodic airflow obstruction.\[[@ref5]\]

The prevalence of Bronchial Asthma has increased continuously since the 1970s, and now affects an estimated 4--7% of the people worldwide.\[[@ref6]\] There has been an increase in the prevalence, and a similar trend is observed in India. Asthma prevalence rates in Karnataka, Gujarat, Haryana, Uttar Pradesh, and Madhya Pradesh are above the national level.\[[@ref7]\] This disease is more predominant in children and aged population. At the age of 6--7 years, the prevalence ranges from 4% to 32%. Apart from being the leading cause of hospitalization for children, it is one of the most important chronic conditions causing elementary school absenteeism.\[[@ref8][@ref9]\]

Despite advancements in the understanding of asthma and the development of new therapeutic strategies, the morbidity and mortality rates due to asthma have increased.\[[@ref10]\] Prognosis is poor if asthma develops in younger age. On the management side, chemotherapy is effective in controlling the severity of attacks and prevents the episodes, but, no disease-modifying effect of chemotherapy is present after the treatment is discontinued.\[[@ref11]\]

Though environmental control measures are important to avoid or eliminate factors that induce or trigger asthma flare-ups; various formulations such as *Ashtangavaleha*,\[[@ref12]\] *Vyaghreehareetakee Avaleha*,\[[@ref13]\] *Shireesha Avaleha*, etc., are available in Ayurvedic classics to manage the condition. The present study is aimed to compare the efficacy of *Ashtangavaleha* (AG) and *Vyaghreehareetakee Avaleha* (VG) on *Tamaka Shwasa* in children.

Materials and Methods {#sec1-2}
=====================

Children with clinical features of *Tamaka Shwasa* with the age limit of 2--16 years of either sex were the research population of the study. The subjects were selected as per the selection criteria from Out Door Patient Department of Kaumarbhritya, IPGT and RA, Gujarat Ayurved University, Jamnagar.

The clinical trial was carried out after obtaining Institutional Ethics Committee (IEC) clearance (PGT/7-A/Ethics/2010--2011/3381 dated. 07/10.01.2011). The trial was registered in Clinical Trial Registry-India (CTRI/2011/10/002059-Trial registered retrospectively). It is a therapeutic, interventional, randomized clinical trial. Computer generated randomization\[[@ref14]\] method was used for generating randomization sequence (seed 22412) and an open trial design was followed. Randomization plan was created on Wednesday March 23 2011 11:40:22 GMT + 0530 (India Standard Time). 100 subjects were randomized into 2 blocks.

Inclusion criteria {#sec2-1}
------------------

Diagnosed cases of *Tamaka Shwasa* -- Bronchial Asthma with at least 3 episodes of asthma symptoms (cough, breathlessness) during the previous yearSeverity as mild to moderate stable asthma defined by Forced Expiratory Volume in 1 s (FEV~1~) \>60% and \<80% of that predicted by Polgar equationAble to generate a peek inspiratory flow rate of 60 L/min\[[@ref15]\]Patients on other drug therapy will be included only after completion of the wash out period prescribed.

Exclusion criteria {#sec2-2}
------------------

Evidence of active concomitants pulmonary disease other than asthmaEvidence of requirement of intubations for asthma, or had been hospitalized for asthma within 1-month before. Had unresolved sinus disease or an unresolved upper or lower respiratory tract infection within 3 weeksMore than 4 short courses of oral corticosteroids within the year preceding the screening visit or any oral corticosteroids in the preceding 4 weeks. Use of astemizole, nedocromil, cromolyn, long acting β agonists, ketotifen, or theophylline within 2 weeks beforeConcomitant severe decompensated systemic disease (cardiovascular, renal, hepatic, endocrine, hematological, neurological, immunological).

Grouping and posology {#sec2-3}
---------------------

Group I (Intervention agent): *Ashtangavaleha* (AG)Group II (Comparator agents) : *Vyaghreehareetakee Avaleha* (VG).

The dose of drug administration was calculated based on Sharngadhara Samhita\'s dose fixation guidelines.\[[@ref16]\] The dose was 5--15 g for both groups depending on the age. In 2--4 years of age group, the dose was 3 g while it was 6 g in 5--7 years, 9 g in 8--10 years, 12 g in 11--13 years and 15 g in Above 13 years age group. The drug was advised to administer in two divided doses *Pragbhakta* (before food) in morning and evening with luke warm water orally. Both the test drugs were procured from Pharmacy, Gujarat Ayurved University, Jamnagar.

Investigations {#sec2-4}
--------------

Complete hemogram and total eosinophils countSerum IgEPulmonary function tests by spirometry and peak expiratory flow (PEF) meterUrine examination -- routine and microscopicStool examination -- routine and microscopic (in suspected cases of worm infestation only).

Assessment criteria {#sec2-5}
-------------------

The assessment was based on the following parameters.

### Primary parameters {#sec3-1}

Improvement in signs and symptoms of *Tamaka Shwasa* vis-a-vis Bronchial Asthma.Scorring pattern*Shwasakashtata* (breathlessness)-(MRC dyspnoea scale)\[[@ref17]\]Not troubled by breathlessness except on strenuous exercise 1Short of breath when hurrying or walking up a slight hill 2Walks slower than contemporaries on level ground because of breathlessness or have to stop for breath when walking at own pace 3Stops for breath after walking about 100 meters or after a few minutes on level ground 4Too breathless to leave the house or breathless when dressing or undressing 5Frequency of *Shwasa Vega*No attack during one month 0Frequency of attack once in a month 1Frequency of attack once in two weeks 2Frequency of attack once in a week 3Frequency of attack twice in a week 4Frequency of attack once or more than once in a day 5*Ghurghurakam* (wheezing)No wheezing 0Wheezing during attack 1Very often wheezing 2Always wheezing found 3*Kasa* (cough)No *Kasa* 0*Kasa Vega* sometimes but not troublesome 1Troublesome *Kasa*, but does not disturbing the sleep 2Very troublesome *Kasa*, does not even allowing to sleep at night 3KaphanistheevanNo *Kaphastheevan* 0Occasional *Kaphastheevan* 1Very often *Kaphastheevan* 2Always *Kaphastheevan* 3*Parshvashula* (chest pain)No pain 0Pain on exertion 1Pain on cough 2Pain during attack 3Persistent pain 4*Peenasa* (coryza)No *Peenasa* 0*Peenasa* along with attack 1*Peenasa* even without attack 2*Peenasa* persisting 3*Na Chapi Nidram Labhate* (night symptoms)No night symptoms 0Sleep disturbed because of slight breathlessness 1Awekening because of breathlessness 2No sleep difficulty of breathlessness whole night 3*Kanthodhvamsa* (irritation in throat)No Kanthodhvamsa 0Occasional *Kanthodhvamsa* 1Very often *Kanthodhvamsa* 2Always *Kanthodhvamsa* 3*Krichchhrabhashitam* (difficulty in speaking)No difficulty in speaking 0Difficulty in speaking during attack 1Difficulty continuous soon after attack 2Difficulty continuous for more time 3Improvement in pulmonary function tests parametersImprovement in frequency and severity in daytime asthma symptoms, overnight asthma symptoms (cough, wheezing, trouble breathing, and activity limitation)Global Initiative for Asthma (GINA) level of asthma control,\[[@ref18]\] Asthma control test (ACT),\[[@ref19]\] Asthma control questioner ACQ.\[[@ref20]\]

### Secondary parameters {#sec3-2}

Positive changes in the blood pictureReduction in Eosinophils countImprovements in IgE antibody levels in serum.

Both groups were assessed before and after the treatment period.

### Assessment of total effect of therapy {#sec3-3}

The improvement in quality of life (QOL parameters)\[[@ref21]\] were considered in all the below mentioned categories for final assessment.

Improved: 100% relief of signs and symptomsMarkedly improved: Improvement between \>75% and 99%Moderately improved: Improvement between \>50% and 75%Mild improvement: Improvement between 25% and 50%Unchanged: No relief in signs and symptoms.

Peak Flow Meter and Spirometry was carried out to those who can perform the test to explore the condition. The follow-up period was of 8 weeks, with fortnight intervals of patient visit for any recurrence of symptoms of *Tamaka Shwasa*.

Statistical analysis {#sec2-6}
--------------------

Comparative efficacy in group AG and VG was assessed by applying the unpaired Student\'s *t*-test.

Observations {#sec1-3}
============

Total 74 patients completed the course of treatment. In group *Ashtangavaleha* (AG), 36 patients while in group *Vyaghreehareetakee Avaleha* (VG), 38 patients completed the course of treatment.

In general obcservations out of 100, maximum number of patients that is 27% belonged to 5-7 years age group, 71% male, 87% of Hindu religion, 48% were from middle group of socioeconomic status. In chief complaints *Shwaskashtata* (breathlessness), *Kasa* (cough) and *Peenas* was noted in 100% patient. *Ghurghurakam* (audible breathing) was complained by 90% patients, expectoration was noted in 70% of patients, 64% patients reported disturbed sleep and *Urah-Parshwa Peeda* (chest pain/chest tightness). Chronicity of *Tamaka Shwasa* (1-5 years) was noted in 65% of patients, family history of asthma was reported in 69% patients.

Results {#sec1-4}
=======

Effect on cardinal symptoms of *Tamaka Shwasa* {#sec2-7}
----------------------------------------------

The variations in the effects of *Ashtangavaleha* and *Vyaghreehareetakee Avaleha* on the symptoms of Tamaka Shwaasa were statistically insignificant except in cough in which the comparator agent showed better result, which was statistically significant \[[Table 1](#T1){ref-type="table"}\].

###### 

Comparative effect on symptoms of *Tamaka Shwasa*

![](AYU-35-384-g001)

The variations in the effects of intervention and comparator agents on Asthma Control Questioner (ACQ) assessments were statistically insignificant except in awakening in night due to asthma (\<0.05), level of asthma control (\<0.001) and asthma control test (ACT) score (\<0.05) in which the intervention agents showed better result, which was statistically significant \[[Table 2](#T2){ref-type="table"}\].

###### 

Comparative effect on ACQ assessments in group AG and VG

![](AYU-35-384-g002)

Effect on hematological parameters {#sec2-8}
----------------------------------

On hematological parameters, group AG showed an increase of total white blood cells, eosinophil, differences in the effects of trial and control drugs on the on the hematological parameters were statistically insignificant except TRBC. On biomarker, both the groups showed an increase in the serum levels of IgE and it was more in group VG, but comparative difference between group AG and group VG was statistically insignificant \[[Table 3](#T3){ref-type="table"}\].

###### 

Comparative effect on biomarker
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Effect on pulmonary function test {#sec2-9}
---------------------------------

### Peak flow meter test {#sec3-4}

Both PEF and FEV~1~ were increased in both groups, and it was more in group AG, but the comparative effect between group AG and group VG were statistically insignificant \[[Table 4](#T4){ref-type="table"}\].

###### 

Comparative effect on peak flow meter
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### Spirometery {#sec3-5}

An increase was observed in FEV~1~, FVC and PEF parameters in both the groups. Increase in FEV~1~, FVC and PEF observed in group AG is greater than group VG, but the difference found is statistically insignificant. FEV~1~/FVC% was increased in group VG while it was decreased in group AG and comparative difference within the groups was found statistically significant \[[Table 5](#T5){ref-type="table"}\].

###### 

Comparative effect on spirometry

![](AYU-35-384-g005)

Effect on quality of life {#sec2-10}
-------------------------

Quality of life was assessed on general, physical, psychological and environmental health parameters. In the domain of general health, both groups showed highly significant results but group AG (42.4%) showed better results than group VG (39.0%) while difference was statistically insignificant. In the domain of physical health, both groups showed highly significant results but group AG (36.2%) showed better results than group VG (35.10%) while difference was statistically insignificant. In the domain of psychological health, both groups showed highly significant results but group AG (42.7%) showed better results than group VG (38.7%) while difference was statistically insignificant. In the domain of social health, both groups showed highly significant results but group AG (41.8%) showed better results than group VG (36.4%) while difference was statistically insignificant. In the domain of environmental health both groups showed highly significant results but group AG (28.6%) showed better results than group VG (24.68%) while difference was statistically insignificant. All the QoL parameters were increased in both groups and group AG showed better results than group VG. While comparing between the group AG and group VG, difference was statistically insignificant \[[Table 6](#T6){ref-type="table"}\].

###### 

Comparative effect on QOL
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Overall effect of therapy {#sec2-11}
-------------------------

When the individualized overall effect of therapy were considered more number of patients in group AG reached moderate improvement zone when compared with group VG. In marked improvement zone, group AG had more number of patients while in mild improvement zone, group VG had more number of patients \[[Table 7](#T7){ref-type="table"}\]. In group AG, overall improvement was 66.66% whereas in group VG, it was 63.15%. While comparing between group AG and VG, the differences was statistically insignificant \[[Table 8](#T8){ref-type="table"}\].

###### 

Individual overall improvement on group AG and VG
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###### 

Comparative overall effect
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Discussion {#sec1-5}
==========

On *Shwasakashtata* (breathlessness), frequency of *Shwasa Vega*, *Ghurghurakam* (wheezing), *Parshvashoola* (chest pain/tightness), *Kaphanishtheevana* (expectoration of thick phlegm), *Shleshma Vimokshante Muhurtam Labhate Shukham* (getting relief after expectoration of thick phlegm), **Peenasa** (coryza), *Na Chaapi Nidraam Labhate* (night symptoms), **Kanthodhvamsa** (irritation in throat) and *Krichchhrabhashita* (difficulty in speaking) both intervention agent *Ashtangavaleha* and the comparator agent *Vyaghreehareetakee Avaleha* showed better results but while comparing between the groups, the difference was insignificant. Thus, changes made were similar in both the groups. In both the groups, *Kasa* (coughing) was decreased *Vyaghreehareetakee Avaleha* showed better results. The ingredients of *Vyaghreehareetakee Avaleha* act as local counter irritants and block the efferent fibers of the vagus which carry the cough stimuli to the cough center.\[[@ref22]\] On the comparison between the groups, the difference was significant (\<0.01). Thus, *Vyaghreehareetakee Avaleha* was found more effective in reducing *Kasa* than *Ashtangaavaleha*.

*Ashtangavaleha* showed promising effect than *Vyaghreeharetakee Avaleha* on ACT score. On ACQ assessments, *Ashtangavaleha* showed better results on awakening in night, awakening at morning due to asthma, limitation of activities, shortness of breathing, wheeze, need of bronchodilator, in comparison to *Vyaghreehareetakee Avaleha*. On total ACQ, changes made by both groups were statistically highly significant but on comparison between groups, the changes made by both formulations were similar and statistically insignificant by *P* \> 0.05. Thus, both formulations have a similar effect on total ACQ. The ingredients of both *Ashtangavaleha* and *Vyaghreehareetakee Avaleha* have immunomodulatory activity, which helps in regulating the allergic responses.\[[@ref23]\] Immunostimulatory activity of aqueous extract of *Kantakari* fruits on mice gives strong evidence that the plant is an immunostimulating agent.\[[@ref24]\]

On hematological parameters, decrease in absolute eosinophil count (AEC) shows a decrease in the magnitude of allergy. Here comparator agent showed better efficacy, so it may be inferred that it is more effective in allergic conditions, but the difference is statistically insignificant. Decrease in erythrocyte sedimentation rate simultaneous decrease in AEC clearly indicates the drugs action on allergic conditions.

In group AG and the change was statistically highly significant by *P* \< 0.001. Similarly in group VG, there was 13.04% increase in PEF and 22.49% in FEV~1~ and change was statistically highly significant by *P* \< 0.001. On the comparison between the groups, difference was statistically insignificant showed similar effect by both formulations. Thus, both formulations were equally effective on peak flow meter measurements and helpful in managing the severity.

On Spirometry, in group AG and changes were statistically insignificant while, in group VG, changes observed were statistically significant (*P* \< 0.05). Comparative changes between group AG and group VG on FEV~1~ and PEF were statistically insignificant. Thus, both formulations have similar effect. A reduced ratio of FEV~1~/forced vital capacity (FVC) indicates obstruction to the flow of air from the lungs. In present trial, FEV~1~/FVC% was increased in group VG. Thus, *Vyaghreehareetakee* showed superiority over *Ashtangavaleha* on this parameter.

Quality of life is a key health indicator that should be routinely assessed. For children, it is important to obtain data on disorders that have an impact on the child and place a burden on the family. The QoL was assessed on general, physical, psychological, social and environmental health parameters. In the domain of all the parameters, both groups showed highly significant results but group AG showed better results than group VG while difference was statistically insignificant. In this study, both agents were highly effective in improving QoL. The formulations were having qualities to increases the *Bala* (strength) which is usually decreased in this condition thus improving the QoL of the child. Due to bio availability enhancer and immunomodulatory activity, the formulations have therapeutic potential for the prevention of allergic diseases. Due to effort made by researcher to educate patient and parents about preservation of the environment, healthy life-style and about exposure to risk factors (concept of *Nidana Parivarjana*), all the parameters of QoL improved significantly in both groups. Thus, all the QoL parameters assessed were improved significantly in both groups, and group AG showed better results than group VG. While comparing between the group AG and VG, difference was statistically insignificant. These profiles indicate that *Tamaka Shwasa* significantly reduces the QoL in the patients. The investigator concluded that patients with bronchial asthma express overall lower levels of QoL.

When the individualized overall effect of therapy was considered, more number of patients in group AG reached moderate improvement zone when compared with group VG. In marked improvement zone, group AG had more number of patients while in mild improvement zone group VG had more number of patients. No patient had complete relief in any group. In no improvement zone both the groups are at par.

This shows a marginal better efficacy of *Ashtangavaleha* in comparison to *Vyaghreehareetakee Avaleha* on the overall condition of the patients presenting with Tamaka Shwasa. There was 66.66% of relief in the overall condition of *Tamaka Shwasa* found in group AG and it was 63.15% in group VG. *Tamak Shwasa* is a multifactorial disorder. The medication that brings *Kaphavilayana*, *Kaphanissarana*, *Srotomardavata*, *Kaasaghna*, *Vatahara*, *Kaphahara* and *Brumhana* effects will be the best in combating the symptoms of *Tamaka Shwasa*. Selected drugs are having *Kapha-Vata* mitigating action *Ushnaveerya* and *Vatanulomana* properties. These are having properties to remove the obstruction made by *Kapha* in the *Pranavaha Srotas* and related system and normalize the functioning of *Vayu*. By virtue of *Rasayana* (immunomodulatory) properties of drugs, they regularize the *Dhatwagni* and promote the normal condition of the child.

Conclusion {#sec1-6}
==========

Above findings inferred that the test drug *Ashtangavaleha* is marginally more effective in comparison to *Vyaghreehareetakee Avaleha* in the management of *Tamaka Shwasa* in children even though the superiority was statistically insignificant (\>0.05).
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